VTGN — Vistagen Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $120.93m
- $58.69m
- $0.49m
- 25
- 10
- 82
- 32
Annual cashflow statement for Vistagen Therapeutics, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.9 | -47.8 | -59.2 | -29.4 | -51.4 |
| Depreciation | |||||
| Non-Cash Items | 2.67 | 4.27 | 3.82 | 2.63 | 4.41 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.08 | -1.92 | 5.59 | 0.793 | 4.76 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -12.1 | -45.3 | -49.7 | -25.8 | -42.1 |
| Capital Expenditures | -0.275 | -0.2 | -0.212 | -0.061 | -0.191 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -0.528 | 0 | -13 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.275 | -0.2 | -0.74 | -0.061 | -13.1 |
| Financing Cash Flow Items | — | 4.04 | -0.174 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 114 | 10.5 | -1.04 | 128 | 3.21 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 102 | -35 | -51.5 | 103 | -52 |